HALLE/SAALE, Germany, May 19, 2014 – Probiodrug AG (Probiodrug), today announced that Dr. Hendrik Liebers, chief financial officer of Probiodrug, will be presenting a corporate update at the annual BioEquity Europe conference, being held 21–22 May 2014. Dr. Liebers’ presentation will take place at 4:20pm local time on 21 May 2014 at the Hilton Amsterdam Hotel in the Netherlands.
Bioequity Europe is an annual collaborative gathering of the corporate and investment communities for the European life sciences. It is designed to be the premier European venue for biopharma companies looking to attract capital and expand their business development efforts. For more information on the conference, please visit www.biocentury.com/conferences/bioequityeurope.
Probiodrug is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic solutions to treat people with Alzheimer’s disease. The Company has medical use and composition of matter patents related to the inhibition of glutaminyl cyclase, providing the Company with a dominant position in this field of research. Probiodrug is backed by institutions such as BB Biotech, Edmond de Rothschild Investment Partners, Goodvent/IBG, HBM, TVM Capital, Life Sciences Partners, Biogen Idec New Ventures, CFH Group, funds managed by Wellington Management and private investors.
Probiodrug’s core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes which play a central role in the maturation of hormones. Probiodrug was founded in 1997 by Prof. Dr. Hans-Ulrich Demuth and Dr. Konrad Glund. For more information, please visit www.probiodrug.de.
Dr. Konrad Glund, CEO
Tel: +49 (345) 555-9900